Is Champions Oncology Stock a Good Investment?
Champions Oncology Investment Advice | CSBR |
- Examine Champions Oncology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Champions Oncology's leadership team and their track record. Good management can help Champions Oncology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact Champions Oncology's business and its evolving consumer preferences.
- Compare Champions Oncology's performance and market position to its competitors. Analyze how Champions Oncology is positioned in terms of product offerings, innovation, and market share.
- Check if Champions Oncology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Champions Oncology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Champions Oncology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Champions Oncology is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Modest | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Champions Oncology Stock
Researching Champions Oncology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 26.0% of the company shares are held by company insiders. The company has Price/Earnings (P/E) ratio of 220.0. Champions Oncology had not issued any dividends in recent years. The entity had 1:12 split on the 12th of August 2015.
To determine if Champions Oncology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Champions Oncology's research are outlined below:
| Champions Oncology had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 50.16 M. Net Loss for the year was (7.28 M) with profit before overhead, payroll, taxes, and interest of 30.22 M. | |
| Champions Oncology currently holds about 8.06 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from insidermonkey.com: Champions Oncology, Inc. Q3 2025 Earnings Call Transcript |
Champions Oncology Quarterly Liabilities And Stockholders Equity |
|
Champions Oncology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Champions Oncology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Champions Oncology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 22nd of July 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 22nd of July 2024 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 30th of April 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Champions Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Champions Oncology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-12-14 | 2020-10-31 | 0.0067 | 1.0E-4 | -0.0066 | 98 | ||
2022-12-13 | 2022-10-31 | -0.01 | -0.0012 | 0.0088 | 88 | ||
2021-12-13 | 2021-10-31 | 0.01 | 0.02 | 0.01 | 100 | ||
2020-09-14 | 2020-07-31 | 0.02 | 0.01 | -0.01 | 50 | ||
2019-12-16 | 2019-10-31 | 0.01 | 0.02 | 0.01 | 100 | ||
2018-12-17 | 2018-10-31 | 0.04 | 0.03 | -0.01 | 25 | ||
2023-12-12 | 2023-10-31 | -0.17 | -0.15 | 0.02 | 11 | ||
2022-03-15 | 2022-01-31 | 0.03 | 0.05 | 0.02 | 66 |
Champions Oncology Target Price Consensus
Champions target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Champions Oncology's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most Champions analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Champions stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Champions Oncology, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationChampions Oncology Target Price Projection
Champions Oncology's current and average target prices are 9.58 and 8.00, respectively. The current price of Champions Oncology is the price at which Champions Oncology is currently trading. On the other hand, Champions Oncology's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Champions Oncology Market Quote on 24th of March 2025
Target Price
Analyst Consensus On Champions Oncology Target Price
Champions Oncology Analyst Ratings
Champions Oncology's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Champions Oncology stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Champions Oncology's financials, market performance, and future outlook by experienced professionals. Champions Oncology's historical ratings below, therefore, can serve as a valuable tool for investors.Know Champions Oncology's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Champions Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Champions Oncology backward and forwards among themselves. Champions Oncology's institutional investor refers to the entity that pools money to purchase Champions Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-12-31 | 26.6 K | Bank Of America Corp | 2024-12-31 | 25.3 K | Cambridge Invest Research Advisors, Inc. | 2024-12-31 | 12.3 K | Mesirow Fin Investmt Mgmt Intl Equity | 2024-12-31 | 12 K | Susquehanna International Group, Llp | 2024-12-31 | 11.5 K | Virtu Financial Llc | 2024-12-31 | 11.1 K | Millennium Management Llc | 2024-12-31 | 10.9 K | Citadel Advisors Llc | 2024-12-31 | 10.9 K | Tower Research Capital Llc | 2024-12-31 | 1.6 K | Battery Management Corp | 2024-12-31 | 2.4 M | Nea Management Company, Llc | 2024-12-31 | 1.7 M |
Champions Oncology's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 132.46 M.Market Cap |
|
Champions Oncology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (1.44) | (1.51) | |
| Return On Assets | (0.25) | (0.26) | |
| Return On Equity | 4.40 | 4.62 |
Determining Champions Oncology's profitability involves analyzing its financial statements and using various financial metrics to determine if Champions Oncology is a good buy. For example, gross profit margin measures Champions Oncology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Champions Oncology's profitability and make more informed investment decisions.
Evaluate Champions Oncology's management efficiency
Champions Oncology has return on total asset (ROA) of 0.1464 % which means that it generated a profit of $0.1464 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3768 %, meaning that it created $0.3768 on every $100 dollars invested by stockholders. Champions Oncology's management efficiency ratios could be used to measure how well Champions Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/24/2025, Return On Equity is likely to grow to 4.62, while Return On Tangible Assets are likely to drop (0.27). At this time, Champions Oncology's Total Assets are relatively stable compared to the past year. As of 03/24/2025, Non Current Assets Total is likely to grow to about 15.1 M, while Intangible Assets are likely to drop slightly above 650.6 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.16) | (0.15) | |
| Tangible Book Value Per Share | (0.19) | (0.18) | |
| Enterprise Value Over EBITDA | (12.56) | (11.93) | |
| Price Book Value Ratio | (39.71) | (41.69) | |
| Enterprise Value Multiple | (12.56) | (11.93) | |
| Price Fair Value | (39.71) | (41.69) | |
| Enterprise Value | 63.5 M | 44.4 M |
Champions Oncology's management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Beta 0.196 |
Basic technical analysis of Champions Stock
As of the 24th of March, Champions Oncology shows the mean deviation of 4.26, and Risk Adjusted Performance of 0.1335. Champions Oncology technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Champions Oncology coefficient of variation, as well as the relationship between the treynor ratio and semi variance to decide if Champions Oncology is priced correctly, providing market reflects its regular price of 9.58 per share. Given that Champions Oncology has jensen alpha of 0.8693, we suggest you to validate Champions Oncology's prevailing market performance to make sure the company can sustain itself at a future point.Champions Oncology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Champions Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Champions Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Champions Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Champions Oncology's Outstanding Corporate Bonds
Champions Oncology issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Champions Oncology uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Champions bonds can be classified according to their maturity, which is the date when Champions Oncology has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Champions Oncology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Champions Oncology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1335 | |||
| Market Risk Adjusted Performance | 0.508 | |||
| Mean Deviation | 4.26 | |||
| Semi Deviation | 4.3 | |||
| Downside Deviation | 4.82 | |||
| Coefficient Of Variation | 708.95 | |||
| Standard Deviation | 5.5 | |||
| Variance | 30.25 | |||
| Information Ratio | 0.1515 | |||
| Jensen Alpha | 0.8693 | |||
| Total Risk Alpha | 1.18 | |||
| Sortino Ratio | 0.1729 | |||
| Treynor Ratio | 0.498 | |||
| Maximum Drawdown | 29.24 | |||
| Value At Risk | (8.06) | |||
| Potential Upside | 9.97 | |||
| Downside Variance | 23.23 | |||
| Semi Variance | 18.48 | |||
| Expected Short fall | (4.87) | |||
| Skewness | 0.4731 | |||
| Kurtosis | 0.6853 |
| Risk Adjusted Performance | 0.1335 | |||
| Market Risk Adjusted Performance | 0.508 | |||
| Mean Deviation | 4.26 | |||
| Semi Deviation | 4.3 | |||
| Downside Deviation | 4.82 | |||
| Coefficient Of Variation | 708.95 | |||
| Standard Deviation | 5.5 | |||
| Variance | 30.25 | |||
| Information Ratio | 0.1515 | |||
| Jensen Alpha | 0.8693 | |||
| Total Risk Alpha | 1.18 | |||
| Sortino Ratio | 0.1729 | |||
| Treynor Ratio | 0.498 | |||
| Maximum Drawdown | 29.24 | |||
| Value At Risk | (8.06) | |||
| Potential Upside | 9.97 | |||
| Downside Variance | 23.23 | |||
| Semi Variance | 18.48 | |||
| Expected Short fall | (4.87) | |||
| Skewness | 0.4731 | |||
| Kurtosis | 0.6853 |
Consider Champions Oncology's intraday indicators
Champions Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Champions Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Champions Oncology Corporate Filings
10Q | 17th of March 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 11th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Champions Stock media impact
Far too much social signal, news, headlines, and media speculation about Champions Oncology that are available to investors today. That information is available publicly through Champions media outlets and privately through word of mouth or via Champions internal channels. However, regardless of the origin, that massive amount of Champions data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Champions Oncology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Champions Oncology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Champions Oncology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Champions Oncology alpha.
Champions Oncology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Champions Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Champions Oncology Corporate Management
| Marianna Zipeto | Research Commercial | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Maria Mancini | Chief Operations | Profile | |
| Karin Heidemann | Executive Operations | Profile | |
| Arthur Hanson | Vice Technology | Profile | |
| BS CMAR | Ex Operations | Profile |
Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.